Guidance
Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers
The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa are a good example. In 2012, the license for the Serum Institute of India’s meningitis A vaccine, MenAfriVac™, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to four days at temperatures of up to 40°C in a controlled temperature chain (CTC). This document provides countries with guidance on when and how to take advantage of this flexibility.
Authors
Languages
Publication year
2013
Type
Guidance
Categories
- Vaccines & delivery devices
Diseases
- Meningococcal meningitis
Organisations
- World Health Organization (WHO)
Tags
- Campaign
- Controlled temperature chain (CTC)
- MenAfriVac
CTC_PUBLICATIONS
You can find more information about "CTC_PUBLICATIONS" in the following Hot Topics:
EPI-CORE-MENINGITIS
OPTIMIZE_CTC
You can find more information about "OPTIMIZE_CTC" in the following Hot Topics:
| Title | Author | Year | Type | Language |
|---|---|---|---|---|
| Controlled temperature chain: Taking advantage of the true heat stability of vaccines | PATH, World Health Organization (WHO) | 2012 | Case study | English, French |
| Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns: guidance for immunization programme decision-makers and managers | World Health Organization (WHO) | 2013 | Guidance | English, French |
